More Articles

Brand-name drugs are not more effective than generic versions for treating cardiovascular disease Generics/Research | Posted 14/09/2009

A recent review in Evidence-Based Medicine by Dr Braden Manns of the University of Calgary in Canada studies the question whether generic drugs are as effective as brand-name drugs for treating car...

Current European biosimilars market may suggest US threat to biotech will be limited Biosimilars/News | Posted 14/09/2009

Though the threat of biosimilars is a hot topic in the US biotech market, their introduction in Europe may reveal that their effects will be limited.

Dutch health insurers obtain biosimilars green light Biosimilars/News | Posted 14/09/2009

Health insurers in The Netherlands are allowed to include biosimilars in their preference policies, the Dutch health ministry has confirmed for the first time, signalling Europe's growing acceptanc...

Biotech drugs need adequate patent protection Biosimilars/News | Posted 14/09/2009

The US government could establish “a properly constructed biosimilars pathway” by providing original developers of biotech drugs with at least 12 years of intellectual property protection to allow...

Generic drug companies adapt to survive Generics/News | Posted 14/09/2009

The prospects seem bright for generics companies. Healthcare systems are increasingly looking for ways to cut costs, and patents are expiring on a growing number of medicines produced by innovative...

Conflicting interpretations of data exclusivity and non-authorised medicinal products Generics/News | Posted 11/09/2009

The European Court of Justice (ECJ) has handed Shire Plc and Janssen-Cilag Ltd, a Johnson & Johnson (J&J) company, a victory against Generics [UK] Ltd in a case involving the Alzheimer's tr...

EvaluatePharma: Generic players impress in the first half Generics/News | Posted 11/09/2009

Which pharma firm is the most profitable? A new analysis of net margins by EvaluatePharma tagged companies for profitability, and the winner was not one of the big pharma companies, e.g. Johnson &a...

EMEA guidelines on biosimilars and clinical implications Guidelines | Posted 10/09/2009

In Europe, the patents of protein products manufactured using biotechnology started to expire in 2000, and more than 10 will have expired by the end of the decade, including patents for growth horm...